SEGMENT REPORTING - Revenue (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) segment	Jun. 30, 2022 USD ($)
Segment reporting
Number of reportable segments | segment			2
Total net revenues	$ 116,547	$ 73,855	$ 223,333	$ 138,332
Depreciation and amortization	14,690	13,764	29,390	28,321
Corporate and other unallocated expenses	38,760	31,958	75,228	60,775
Operating Income (Loss)	12,402	(12,913)	22,297	(32,108)
Interest expense, net	(7,100)	(6,669)	(14,796)	(13,282)
Other (expense) income, net	(53)	764	(87)	675
Income (Loss) Before Income Tax Benefit	5,249	(18,818)	7,414	(44,715)
Operating Segments | Generics, Established Brands, and Other
Segment reporting
Total net revenues	92,243	63,653	182,699	126,838
EBITDA	39,937	15,473	78,765	30,004
Operating Segments | Rare Disease
Segment reporting
Total net revenues	24,304	10,202	40,634	11,494
EBITDA	4,215	(6,663)	2,964	(17,111)
Corporate, Non-Segment
Segment reporting
Depreciation and amortization	(14,690)	(13,764)	(29,390)	(28,321)
Corporate and other unallocated expenses	(17,060)	(7,959)	(30,042)	(16,680)
Operating Income (Loss)	12,402	(12,913)	22,297	(32,108)
Interest expense, net	(7,100)	(6,669)	(14,796)	(13,282)
Other (expense) income, net	$ (53)	$ 764	$ (87)	$ 675